CVACX Performance — Calamos Select Fund, Class C
Data updated: 2026-09-29
CVACX returned +4.91% year to date and +10.66% over one year to Jul 2026. Annualised returns are +15.78% over 3 years and +9.56% over 5 years. The fund trailed its US Large Value category average: $100 invested three years ago grew to $155, against $156 for the category, and to $111 over one year, against $122. Volatility over the past three years was 13.54% a year. In the 12 months to Jul 2026 the fund lost a net $616K, and assets reached $63.71M.
CVACX Growth of $100
What $100 invested in Calamos Select Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the US Large Value category average over the same months.
| Period | CVACX | Category average |
|---|---|---|
| 1 year (Aug 2025 – Jul 2026) | $111 | $122 |
| 3 years (Aug 2023 – Jul 2026) | $155 | $156 |
| 5 years (Aug 2021 – Jul 2026) | $158 | $168 |
| Since data start (Aug 2019 – Jul 2026) | $229 | $226 |
CVACX Trailing Returns
Total returns to Jul 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +4.91% |
| 1 year | +10.66% |
| 3 years (annualised) | +15.78% |
| 5 years (annualised) | +9.56% |
CVACX Annual Returns
Calendar-year total returns of Calamos Select Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jul) | +4.91% |
| 2025 | +14.20% |
| 2024 | +23.10% |
| 2023 | +25.41% |
| 2022 | −19.41% |
| 2021 | +23.97% |
| 2020 | +15.49% |
| 2019 (Aug–Dec) | +7.46% |
CVACX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | −0.1% | −2.8% | −5.2% | +10.4% | +3.4% | −0.1% | −0.1% | — | — | — | — | — |
| 2025 | +3.1% | −1.2% | −7.1% | +0.2% | +6.7% | +5.2% | +1.7% | +2.1% | +1.8% | +2.1% | −0.1% | −0.5% |
| 2024 | +2.3% | +5.5% | +2.2% | −3.5% | +4.5% | +5.0% | −1.0% | +2.0% | +1.6% | −1.0% | +6.2% | −2.4% |
| 2023 | +5.5% | −2.9% | +3.6% | +2.2% | +1.0% | +5.9% | +2.7% | −1.5% | −5.1% | −1.4% | +9.6% | +4.2% |
| 2022 | −5.8% | −2.4% | +3.6% | −9.1% | −1.2% | −7.1% | +8.9% | −3.4% | −8.7% | +7.6% | +4.7% | −6.3% |
| 2021 | −1.6% | +3.9% | +2.5% | +6.2% | −0.1% | +2.9% | +2.3% | +2.6% | −4.7% | +7.0% | −2.0% | +3.3% |
| 2020 | −1.3% | −8.5% | −14.9% | +12.6% | +7.1% | +1.3% | +5.7% | +7.1% | −4.2% | −2.9% | +11.5% | +4.7% |
| 2019 | — | — | — | — | — | — | — | −1.9% | +1.8% | +1.5% | +2.8% | +3.1% |
CVACX Risk
Risk measures from monthly returns over Aug 2023 – Jul 2026.
- 3-year volatility (annualised): 13.54%
- 3-year Sharpe ratio: 0.83 (vs 4.5% risk-free rate)
- Best month: +10.45% (Apr 2026)
- Worst month: −7.12% (Mar 2025)
CVACX Fund Flows
Monthly money in and out of Calamos Select Fund, from SEC Form N-PORT.
- 12-month net flow: −$616K
- 12-month gross sales (incl. reinvestments): $4.2M
- Sales ÷ redemptions: 0.87×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jul 2026 | $49K | $142K | −$93K |
| Jun 2026 | $281K | $165K | $117K |
| May 2026 | $195K | $130K | $65K |
| Apr 2026 | $1K | $135K | −$134K |
| Mar 2026 | $28K | $223K | −$194K |
| Feb 2026 | $12K | $634K | −$622K |
| Jan 2026 | $92K | $140K | −$48K |
| Dec 2025 | $3.1M | $667K | $2.5M |
| Nov 2025 | $259K | $837K | −$578K |
| Oct 2025 | $79K | $195K | −$116K |
| Sep 2025 | $1K | $283K | −$281K |
| Aug 2025 | $25K | $1.2M | −$1.2M |
CVACX Assets Under Management
Net assets of Calamos Select Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-07-31 | $63.71M |
| 2026-04-30 | $61.52M |
| 2026-01-31 | $61.31M |
| 2025-10-31 | $62.86M |
| 2025-07-31 | $60.70M |
| 2025-04-30 | $53.80M |
| 2025-01-31 | $58.98M |
| 2024-10-31 | $56.11M |
| 2024-07-31 | $55.21M |
| 2024-04-30 | $51.05M |
| 2024-01-31 | $49.93M |
| 2023-10-31 | $43.31M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.